Laboratory Services was Insight Molecular Diagnostics’s largest product and service line in fiscal 2025, bringing in $4.03M of $4.06M (99%).
| Product and Service | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Laboratory Services | — | $1.86M | $4.03M |
| Pharma Services | $1.47M | — | — |
| Laboratory Developed Test Services | $36.00K | $22.00K | — |
| Kitted Products | — | — | $24.00K |
| Total | $1.50M | $1.88M | $4.06M |
Insight Molecular Diagnostics brought in $4.06M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Insight Molecular Diagnostics regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $1.88M. Laboratory Services was the largest at $4.03M (99.4%), ahead of Kitted Products at $24.00K (0.6%).
Insight Molecular Diagnostics began breaking out Laboratory Services in fiscal 2024 and Kitted Products in fiscal 2025. Insight Molecular Diagnostics stopped reporting Pharma Services ($1.47M in fiscal 2023) and Laboratory Developed Test Services ($22.00K in fiscal 2024) as separate lines.
United States was Insight Molecular Diagnostics’s largest region in fiscal 2025, bringing in $4.03M of $4.06M (99%).
| Geography | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| United States | $923.00K | $1.67M | $4.03M |
| United Kingdom | $409.00K | $45.00K | — |
| Asia Pacific | $160.00K | $145.00K | — |
| Europe | — | $18.00K | $24.00K |
| Spain | $11.00K | — | — |
| Total | $1.50M | $1.88M | $4.06M |
Insight Molecular Diagnostics brought in $4.06M from its two regions in fiscal 2025, the year ended December 31, 2025. Insight Molecular Diagnostics regrouped these regions after fiscal 2024, so the total does not compare directly with that year's $1.88M. United States was the largest at $4.03M (99.4%), ahead of Europe at $24.00K (0.6%).
Insight Molecular Diagnostics began breaking out Europe in fiscal 2024, when it brought in $18.00K. Insight Molecular Diagnostics stopped reporting Asia Pacific ($145.00K in fiscal 2024), United Kingdom ($45.00K in fiscal 2024) and Spain ($11.00K in fiscal 2023) as separate regions.
Laboratory Services was Insight Molecular Diagnostics’s largest revenue line in fiscal 2025, bringing in $4.03M of $4.06M (99%).
| Statement of Income Location, Balance | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Laboratory Services | — | — | $1.86M | $4.03M |
| Pharma Services | $958.00K | $1.47M | — | — |
| Laboratory Developed Test Services | — | $36.00K | $22.00K | — |
| Kitted Products | — | — | — | $24.00K |
| Total | $958.00K | $1.50M | $1.88M | $4.06M |
Insight Molecular Diagnostics brought in $4.06M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. Insight Molecular Diagnostics regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $1.88M. Laboratory Services was the largest at $4.03M (99.4%), ahead of Kitted Products at $24.00K (0.6%).
Insight Molecular Diagnostics began breaking out Laboratory Services in fiscal 2024 and Kitted Products in fiscal 2025. Insight Molecular Diagnostics stopped reporting Pharma Services ($1.47M in fiscal 2023) and Laboratory Developed Test Services ($22.00K in fiscal 2024) as separate revenue lines.
Insight Molecular Diagnostics (IMDX) reports its revenue by product and service, by geography and by statement of income location, balance. In fiscal 2025, Laboratory Services was its largest product and service line, bringing in $4.03M (99.4% of the total), followed by Kitted Products at $24.00K (0.6%).
Laboratory Services was Insight Molecular Diagnostics' largest product and service line in fiscal 2025, bringing in $4.03M, or 99.4% of the $4.06M total across its two product and service lines.
United States was Insight Molecular Diagnostics' largest region in fiscal 2025, bringing in $4.03M, or 99.4% of the $4.06M total across its two regions.
Laboratory Services was Insight Molecular Diagnostics' largest revenue line in fiscal 2025, bringing in $4.03M, or 99.4% of the $4.06M total across its two revenue lines.
Every figure comes from Insight Molecular Diagnostics' annual financial filings, as reported. Each line keeps the name Insight Molecular Diagnostics gives it, and years follow its fiscal calendar.
Insight Molecular Diagnostics' revenue by product and service goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.